1. Moore D, Bartlett JG: Combination antiretroviral therapy in HIV infection: An economic perspective. PharmacoEconomics 10(2):109-113, 1996

  2. Feinberg MB: Changing the natural history of HIV disease. Lancet 348:239-246, 1996

  3. O’Brien TR et al: Serum HIV-1 RNA levels and time to development of AIDSin the multicenter hemophilia cohort study. JAMA 276(2):105, 1996

  4. Mellors JW et al: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 271:1167, 1996

  5. Pantaleo G et al: HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362:355, 1993

  6. Xiping W et al: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117, 1995

  7. Marengère LEM et al: Regulation of T cell receptor signalling by tyrosine phosphatase SYP association with CTLA-4. Science 272:1170, 1996

  8. Condra JH, Emini EA: Preventing HIV-1 drug resistance: Science & Medicine (Jan/Feb):14, 1997

  9. Carpentier CCJ et al: Consensus Statement: Antiretroviral therapy for HIV infection in 1996: Recommendations of an international panel. JAMA 276(2):146, 1996

  10. From the Centers for Disease Control and Prevention: Leads from the Morbidity and Mortality Weekly Report, Atlanta, GA: Update: Provisional public health service recommendations for chemoprophylaxis after occupational exposure to HIV. JAMA 276(2):90, 1996

Derechos reservados ©2019  Merck Sharp & Dohme I.A. Corp. Una subsidiaria de Merck & Co., Inc., Kenilworth, NJ, USA. Todos los derechos reservados.
Este sitio es solamente para los residentes de Centroamérica y República Dominicana